|
Codexis, Inc. (CDXS) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Codexis, Inc. (CDXS) Bundle
Evaluieren Sie Codexis, Inc. (CDXS) finanzielle Aussichten wie ein Fachmann! Dieser (CDXS) DCF-Taschenrechner (CDXS) bietet vorgefüllte Finanzdaten und vollständige Flexibilität, um das Umsatzwachstum, WACC, Margen und andere kritische Annahmen zu ändern, um sich an Ihren Vorhersagen auszurichten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 69.1 | 104.8 | 138.6 | 70.1 | 59.3 | 62.2 | 65.2 | 68.3 | 71.6 | 75.0 |
| Revenue Growth, % | 0 | 51.69 | 32.3 | -49.39 | -15.39 | 4.8 | 4.8 | 4.8 | 4.8 | 4.8 |
| EBITDA | -19.4 | -16.8 | -23.1 | -49.3 | -58.5 | -28.6 | -29.9 | -31.4 | -32.9 | -34.4 |
| EBITDA, % | -28.04 | -15.99 | -16.64 | -70.26 | -98.61 | -45.91 | -45.91 | -45.91 | -45.91 | -45.91 |
| Depreciation | 4.6 | 5.9 | 10.3 | 9.9 | .0 | 4.2 | 4.4 | 4.6 | 4.8 | 5.1 |
| Depreciation, % | 6.59 | 5.68 | 7.4 | 14.15 | 0 | 6.76 | 6.76 | 6.76 | 6.76 | 6.76 |
| EBIT | -23.9 | -22.7 | -33.3 | -59.2 | -58.5 | -32.8 | -34.3 | -36.0 | -37.7 | -39.5 |
| EBIT, % | -34.64 | -21.67 | -24.04 | -84.41 | -98.61 | -52.67 | -52.67 | -52.67 | -52.67 | -52.67 |
| Total Cash | 150.1 | 116.8 | 114.0 | 65.1 | 73.5 | 59.1 | 61.9 | 64.9 | 68.0 | 71.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 29.3 | 37.7 | 40.9 | 19.9 | 14.7 | 20.0 | 21.0 | 22.0 | 23.1 | 24.2 |
| Account Receivables, % | 42.41 | 35.94 | 29.49 | 28.41 | 24.72 | 32.2 | 32.2 | 32.2 | 32.2 | 32.2 |
| Inventories | 1.0 | 1.2 | 2.0 | 2.7 | 1.8 | 1.3 | 1.4 | 1.5 | 1.6 | 1.6 |
| Inventories, % | 1.4 | 1.11 | 1.46 | 3.83 | 3.03 | 2.17 | 2.17 | 2.17 | 2.17 | 2.17 |
| Accounts Payable | 3.0 | 3.0 | 3.2 | 5.9 | 2.8 | 2.8 | 3.0 | 3.1 | 3.3 | 3.4 |
| Accounts Payable, % | 4.3 | 2.86 | 2.34 | 8.48 | 4.78 | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 |
| Capital Expenditure | -3.7 | -13.8 | -8.3 | -4.4 | -4.3 | -4.7 | -5.0 | -5.2 | -5.5 | -5.7 |
| Capital Expenditure, % | -5.43 | -13.2 | -5.99 | -6.3 | -7.25 | -7.63 | -7.63 | -7.63 | -7.63 | -7.63 |
| Tax Rate, % | -0.05211367 | -0.05211367 | -0.05211367 | -0.05211367 | -0.05211367 | -0.05211367 | -0.05211367 | -0.05211367 | -0.05211367 | -0.05211367 |
| EBITAT | -24.3 | -22.9 | -33.6 | -59.3 | -58.5 | -32.8 | -34.3 | -36.0 | -37.7 | -39.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -50.7 | -39.3 | -35.5 | -30.8 | -59.8 | -38.2 | -35.8 | -37.5 | -39.3 | -41.2 |
| WACC, % | 11.92 | 11.92 | 11.92 | 11.92 | 11.92 | 11.92 | 11.92 | 11.92 | 11.92 | 11.92 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -138.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -42 | |||||||||
| Terminal Value | -424 | |||||||||
| Present Terminal Value | -241 | |||||||||
| Enterprise Value | -379 | |||||||||
| Net Debt | 41 | |||||||||
| Equity Value | -420 | |||||||||
| Diluted Shares Outstanding, MM | 73 | |||||||||
| Equity Value Per Share | -5.72 |
What You Will Get
- Real CDXS Financials: Includes historical and forecasted data for precise valuation.
- Adjustable Inputs: Modify WACC, tax rates, revenue growth, and capital expenditures.
- Automatic Calculations: Intrinsic value and NPV are calculated dynamically.
- Scenario Analysis: Test multiple scenarios to assess Codexis’ future performance.
- Clear and Intuitive Design: Designed for professionals while remaining user-friendly for beginners.
Key Features
- Advanced DCF Calculator: Features comprehensive unlevered and levered DCF valuation models tailored for Codexis, Inc. (CDXS).
- WACC Calculator: Ready-to-use Weighted Average Cost of Capital sheet with adjustable inputs specific to Codexis, Inc. (CDXS).
- Editable Forecast Assumptions: Customize growth rates, capital expenditures, and discount rates for Codexis, Inc. (CDXS).
- Built-In Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Codexis, Inc. (CDXS).
- Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis of Codexis, Inc. (CDXS).
How It Works
- Step 1: Download the Excel file for Codexis, Inc. (CDXS).
- Step 2: Examine the pre-filled financial data and forecasts for Codexis.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify your assumptions.
- Step 5: Evaluate the results and leverage the findings for your investment strategies.
Why Choose This Calculator for Codexis, Inc. (CDXS)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and industry consultants.
- Accurate Data: Codexis’ historical and forecasted financials are preloaded for precise analysis.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Instantly calculates intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth calculation experience.
Who Should Use This Product?
- Investors: Accurately estimate Codexis, Inc.'s (CDXS) fair value before making investment decisions.
- CFOs: Leverage a professional-grade DCF model for financial reporting and analysis related to Codexis, Inc. (CDXS).
- Consultants: Quickly adapt the template for valuation reports for clients focused on Codexis, Inc. (CDXS).
- Entrepreneurs: Gain insights into financial modeling used by leading biotech companies like Codexis, Inc. (CDXS).
- Educators: Use it as a teaching tool to demonstrate valuation methodologies relevant to Codexis, Inc. (CDXS).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Codexis historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Codexis, Inc. (CDXS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.